Astrana Health, Inc. (ASTH) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024. Astrana Health, Inc. is a provider-centric, technology-powered, risk-bearing healthcare company operating an integrated delivery platform. The company manages care for approximately 1.1 million patients through a network of over 10,000 contracted physicians across California, Nevada, Texas, Maryland, Connecticut, Georgia, and Hawaii. Operations are organized into three reportable segments: Care Partners (risk-bearing organizations), Care Delivery (clinics and ancillary services), and Care Enablement (technology and management services).
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value | Change |
|---|---|---|---|
| Total Revenue | $2,034.5 million | $1,386.7 million | +47% |
| Net Income (GAAP) | $49.9 million | $57.8 million | -14% |
| Net Income Attributable to Astrana | $43.1 million | $60.7 million | -29% |
| Adjusted EBITDA | $170.4 million | $146.6 million | +16% |
| Adjusted EBITDA Margin | 8% | 11% | -300 bps |
| Operating Cash Flow | $52.2 million | $68.2 million | -23% |
| Total Debt (Gross) | $438.1 million | $282.0 million | +55% |
| Cash & Equivalents | $288.5 million | $293.8 million | -2% |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by acquisitions in the Care Partners segment and the transition of enrollees to full-risk arrangements via Restricted Knox-Keene plans. Capitation revenue increased 53% to $1.86 billion.
- Profitability Decline: Net income attributable to Astrana decreased 29% due to a 106% increase in interest expense (driven by higher debt levels) and increased income attributable to non-controlling interests. This was partially offset by an unrealized gain on investments.
- Segment Performance:
- Care Partners: Revenue +52%, Operating Income +54%.
- Care Delivery: Revenue +16%, Operating Income -98% (due to costs from new clinic openings).
- Care Enablement: Revenue +14%, Operating Income -4%.
- Acquisitions: Significant M&A activity included the acquisition of Collaborative Health Systems (CHS), Advanced Health Management Systems (AHMS), and Community Family Care Medical Group (CFC), totaling approximately $255.8 million in consideration.
Guidance, Outlook, and Risks
- Prospect Medical Holdings Acquisition: On November 8, 2024, Astrana agreed to acquire certain assets and businesses of Prospect Medical Holdings for $745.0 million. The transaction is subject to regulatory approvals and Bankruptcy Court approval (Prospect filed for Chapter 11 bankruptcy in January 2025). Closing is anticipated in mid-2025.
- Financing: In February 2025, the company entered a new credit agreement providing a $300 million revolver, a $250 million Term Loan A, and a $745 million delayed draw term loan specifically to finance the Prospect transaction.
- Key Risks:
- Transaction Risk: The Prospect acquisition faces uncertainty due to the seller's bankruptcy proceedings and regulatory hurdles.
- Regulatory Compliance: Significant exposure to federal and state healthcare laws (False Claims Act, Anti-Kickback Statute, Stark Law) and corporate practice of medicine laws.
- Financial Solvency: The company must maintain specific cash-to-claims ratios and tangible net equity requirements under California DMHC regulations.
- Concentration: Four payers accounted for 66.2% of total net revenue in 2024.
Investor Verification Checklist
- Prospect Transaction Status: Verify the current status of the Bankruptcy Court approval and regulatory clearance for the $745 million Prospect acquisition.
- Debt Covenants: Review the specific financial covenants (leverage and interest coverage ratios) in the new February 2025 credit agreement and assess compliance given the increased debt load.
- Non-Controlling Interests: Analyze the impact of the "Mezzanine Deficit" and non-controlling interests (specifically Allied Physicians of California) on net income attributable to common shareholders.
- Medical Liabilities: Scrutinize the actuarial assumptions used for Incurred But Not Reported (IBNR) claims, which totaled $209.0 million, as this is a critical audit matter.
- Regulatory Exposure: Confirm ongoing compliance with California's Knox-Keene Act and corporate practice of medicine laws, particularly regarding the consolidation of Variable Interest Entities (VIEs).